Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Share News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.25
Bid: 34.25
Ask: 35.45
Change: -1.075 (-2.99%)
Spread: 1.20 (3.504%)
Open: 36.00
High: 36.00
Low: 34.00
Prev. Close: 35.925
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Futura Medical rises on financing transaction

Thu, 04th Mar 2021 11:42

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Futura Medical, up 22% at 20.08 pence, 12-month range 7.16p-24.49p. The pharmaceutical company says it has entered into financing transactions with HT Riverwood Multi-Growth Fund which will provide the company with up to GBP2 million in cash, GBP1.5 million of which has been received.

----------

Franchise Brands, up 7.7% at 109.30p, 12-month range 81p-136.65p. Says it saw a resilient performance through lockdowns and a robust recovery in second half. For 2020, revenue increases by 12% to GBP49.3 million from GBP44.0 million in 2019 and pretax profit increases to GBP3.7 million from GBP3.3 million. Franchise Brands ups final dividend to 0.80p per share from 0.65p paid in 2019.

----------

ThinkSmart, up 6.7% at 77.9p, 12-month range 12p-91.5p. The digital payments business posts rise in interim earnings. For six months to December 31, pretax profit surges to GBP53.7 million from GBP16.0 million after financial instruments gains. ThinkSmart pays 3.4p per share special dividend and capital return in December.

----------

AIM - LOSERS

----------

MediaZest, down 16% at 0.080p, 12-month range 0.01p-0.18p. The audio-visual company says financial results for the eighteen-month period were affected substantially by the Covid-19 pandemic, with reduction in revenue particularly during the first UK lockdown. Revenue GP3.1 million, down from GBP3.3 million year before and swings to GBP478,000 pretax loss from GBP6,000 profit.

----------

Angle, down 9.7% at 79.30p, 12-month range 37.15p-98p. The liquid biopsy company says it has received response from US Food & Drug Administration after requesting clearance for its Parsortix treatment. Says FDA has indicated its review processes for non Covid-19 devices are currently slower than usual due to pandemic priorities. Notes that FDA processes are outside the company's control and it is continuing to expedite all aspects of the process which are under its control in line with previously advised timescales.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2013 13:26

Futura Medical signs marketing and distribution deal with Church & Dwight

Futura Medical, a pharmaceutical group that develops innovative products for consumer healthcare, has signed an agreement with Church & Dwight Co., for the marketing and distribution of CSD500, Futura's new condom product under the Trojan brand. Under the terms of the agreement, Church & Dwight wi

Read more
9 Jan 2013 16:15

Chairman and CEO of Mediterranean Oil & Gas stock up

Both the Chairman and Chief Executive of Mediterranean Oil & Gas (MOG) increased their holdings in the company on Tuesday, one day after it said it was 'pleased' with its production activities in Italy last year, setting the stage for a strong 2013. CEO William Higgs purchased 200,000 shares at 10

Read more
14 Sep 2012 08:46

Future Medical places shares at tiny discount

Futura Medical, best known for its condom products which help maintain a firmer erection during sexual intercourse, is to raise funds through a placing of shares at a tiny discount to the prevailing share price. The company intends to raise £2.08m, gross, through the placing of 3.65m shares at 57p

Read more
28 Aug 2012 11:24

Fall-out between Reckitt Benckiser and Futura over CSD 500

The British firm that says it has created an erection sustaining condom has fallen out with its marketing partner, Reckitt Benckiser, forcing it to go ahead with production on its own. Futura Medical says it was unable to find: "common ground acceptable to both parties in respect of their continued

Read more
14 Feb 2011 14:28

Futura expects lower loss

AIM-quoted erectile dysfunction treatments developer Futura Medical says that its loss fell in 2010. Revenues generated from commercial payments from partners increased from £50,000 to £125,000. The loss fell from £1.51m to £1.32m. There is still £1m in the bank. The CSD500 condom still requir

Read more
29 Jan 2011 14:04

Takeover targets named

Hold on tight, a wave of patent expiries and generic competition could spark another round of consolidation in the pharma and medical devices sector this year. Billions of dollars have been spent on takeovers or pumped into new issues in recent months as confidence in the recovery grows and cash-ri

Read more
18 Jan 2011 16:37

Futura hit by more delays to CSD500

Erectile dysfunction treatments developer Futura Medical says that there will be further delays in the CSD500 condom getting its CE mark but management believes that the regulator's queries can be addressed in a relatively short period of time. The CSD500 condom helps men to maintain a firm erect

Read more
23 Dec 2010 11:37

Small caps round-up: Forte Energy, Futura Medical, Hightex...

Forte Energy has completed a 7,000m drilling program at its A238 uranium anomaly in the north of its leases in Mauritania and a 1,500m diamond drilling program should be completed next month. "These initial results are from the first pass shallow drilling along strike, and confirm the presence of

Read more
8 Sep 2010 16:36

London close: US spurs Footsie recovery

Footsie put its weak start behind it to close with good gains, helped by buoyant trading on Wall Street. US shares recovered from losses yesterday that snapped a recent winning streak. Among the risers here was ARM Holdings. UBS has issued a downbeat assessment of the European semiconductor mark

Read more
8 Sep 2010 14:28

London afternoon: ARM in line for Samsung boost

Footsie emerged from the lunch-time session nursing a small gain, with the majority of the blue-chip index's constituents in positive territory. Chief among them was chip designer ARM Holdings. UBS has issued a downbeat assessment of the European semiconductor market but it has made an exception o

Read more
8 Sep 2010 12:59

Small caps round-up: Ark Therapeutics, Alkane Energy, CPL

Speciality drug developer AGI Therapeutics posted narrower losses in the six months to June 30 and said it was on the look-out for 'external opportunities.' The company, which is developing treatments for gastrointestinal disorders and multiple sclerosis, saw pre-tax losses narrow to $3.1m from $9.

Read more
21 Jul 2010 11:05

CORRECT: =3rd UPDATE: Reckitt Benckiser In GBP2.54B SSL Deal

("=3rd UPDATE: Reckitt Benckiser Agrees GBP2.54B Offer For SSL," at 0911 GMT, misstated Reckitt's total workforce in the last paragraph. The correct version follows:) (Adds detail and analyst's comment.) By Jason Douglas and Michael Carolan Of DOW JONES NEWSWIRES LONDON (Dow Jones)-

Read more
30 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Resaca Exploration Shelves Share Sale

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps RESACA EXPLOITATION INC. (RSOX.LN), an oil and gas company, said Wednesday it postponed a planned share issue due to market conditions. Resaca planne

Read more
30 Jun 2010 12:30

UK SMALLCAP ROUNDUP: HMV Strategy On Track Amid Record Sales

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps HMV GROUP PLC (HMV.LN) Wednesday said its strategy of diversifying its business away from CDs and DVDs remains on track, although the CD market didn't de

Read more
30 Jun 2010 08:56

Futura Medical Signs Development Deal With GlaxoSmithKline

LONDON (Dow Jones)--Pharmaceutical company Futura Medical PLC (FUM.LN) Tuesday said it signed a deal with GlaxoSmithKline PLC's (GSK.LN) cosumer healthcare unit to develop a painkiller. GlaxoSmithKline will be responsible for the clinical and regulatory development of Futura's TR100 and Futura w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.